

Role of Digoxin in Preventing Cigarette Smoke-Induced COPD via HIF-1 α Inhibition in a Mouse Model

Kedong Zhang^{1,*}, Feng Zhou^{1,2,*}, Caixia Zhu³, Liang Yuan⁴, Defu Li⁴, Jian Wang⁴, Wenju Lu⁴

¹Department of Pulmonary and Critical Care Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China;

²Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xian, Shaanxi, People's Republic of China; ³Department of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China; ⁴State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Department of Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China

*These authors contributed equally to this work

Correspondence: Wenju Lu; Jian Wang, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Department of Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, People's Republic of China, Tel +86-20-83205040, Email wlu92@qq.com; jianwang@gzhmu.edu.cn

Purpose: Hypoxia-inducible factor-1 α (HIF-1 α) plays an important regulatory role in inflammatory and hypoxic diseases. Higher HIF-1 α level was found in the lungs of chronic obstructive pulmonary disease (COPD) patients, however, its role in cigarette smoke (CS)-induced COPD has not been fully studied. Digoxin has been showed to inhibit HIF-1 α translation and block HIF-1 α activity and thus is often used as the HIF-1 α inhibitor. Therefore, in the present study, we chose digoxin as the inhibitor to investigate whether HIF-1 α contributes to the progression in a mouse model of COPD and possible mechanism.

Methods: The COPD model was established by cigarette smoke (CS) exposed; animals were intragastrically treated with vehicle or different doses of digoxin (0.02 mg/kg and 0.1 mg/kg). COPD associated phenotypes such as pathological changes in lungs, inflammation, lung function and mucus secretion in airways were evaluated. Meanwhile, cigarette smoke extract (CSE) treated A549 cells were administrated with digoxin (50nM) or Smad3 inhibitor (S7959 100uM). Moreover, EMT associated markers together with HIF-1 α /TGF- β 1/Smad3 signaling pathway were detected both in vivo and in vitro.

Results: The level of HIF-1 α was significantly increased in lungs of COPD mice and CSE-exposed A549 cells, which was markedly suppressed by digoxin. Moreover, digoxin inhibited CS-induced inflammatory responses, lung function decline, and mucus hypersecretion in COPD mouse model. In vitro studies, digoxin decreased CSE-induced pro-inflammatory cytokine release. Importantly, CS-induced or CSE-induced EMT and up-regulation of HIF-1 α /TGF- β 1/Smad pathway were inhibited by digoxin in vitro. Additionally, S7959 mitigated CSE-induced EMT in A549 cells.

Conclusion: Digoxin can protect CS-induced COPD and prevent CS-induced EMT possibly through HIF-1 α /TGF- β 1/Smad3 signaling pathway in mice. This study suggests HIF-1 α could be a potential intervention target for COPD prevention and treatment, especially for EMT in CS-induced COPD.

Keywords: COPD, cigarette smoke, HIF-1 α , digoxin, EMT

Introduction

Chronic obstructive pulmonary disease (COPD), a progressive lung disease, is mostly caused by long-term smoke¹ and predicted to be the third leading cause of death globally by 2020.^{2,3} Its pathological changes mainly include emphysema, respiratory structural remodeling, and airway goblet cell hyperplasia and mucus hyper-secretion.⁴ The commonly used medications for COPD are mainly bronchodilators and inhaled corticosteroids, but they cannot slow down lung function

decline and improve the prognosis.² Therefore, there is an enormous need for us to find new intervention target or develop new drugs to improve the progression and prognosis of COPD.

Hypoxia-inducible factor-1 α (HIF-1 α), a subunit of heterodimeric transcription factor HIF-1, activates the transcription of target genes under hypoxia conditions.⁵ Moreover, it is an important regulator of cellular responses to inflammation and oxidants.⁶ Some studies also reported that HIF-1 α might promote inflammatory responses,^{7,8} airway goblet cell hyperplasia,⁹ and emphysema¹⁰ in COPD. However, its role in cigarette smoke (CS)-induced COPD has not been fully studied, especially in COPD-related epithelial–mesenchymal transition (EMT).

EMT of airway epithelium is increased in COPD patients and normal smokers, and it contributes greatly to the occurrence and progression of COPD.^{11–13} Moreover, EMT is involved in the respiratory structural remodeling and airway fibrosis in COPD.¹⁴ Among them, EMT is a crucial process during embryogenesis (type 1 EMT) but may also be induced by persistent injury and inflammation. Severe or even complete organ fibrosis (type 2 EMT) and association with malignancy (type 3 EMT) may occur due to active EMT; both processes may be associated with the pathology of COPD. But so far, the role of HIF-1 α on EMT in CS-induced COPD has not been reported. HIF-1 α plays a key role in the EMT of renal fibrosis and mammary cancer cells.^{15,16} Transforming growth factor- β 1 (TGF- β 1)/Smad pathway plays a crucial role in triggering EMT.¹⁷ Phosphorylated Smad2 and Smad3 form a stable complex with Smad4 and then transfer into the nucleus, subsequently modulating the transcription of EMT-associated genes.¹⁸ Besides, HIF-1 α protein synthesis can regulate the activation of the TGF- β 1/Smad signaling pathway.¹⁹ Therefore, HIF-1 α might contribute to the progression of EMT in COPD through the TGF- β 1/Smad signaling pathway.

Digoxin has been shown to inhibit HIF-1 α protein translation and block HIF-1 activity and thus is often used as a HIF-1 α inhibitor.^{20,21} Therefore, in this study, we investigated the effects of HIF-1 α inhibitor on CS-induced COPD by administrating the CS-exposed mice or cigarette smoke extract (CSE)-stimulated A549 cells. Furthermore, we determined whether HIF-1 α contributed to the progression of EMT in COPD and whether this effect was mediated through the TGF- β 1/Smad signaling pathway.

Materials and Methods

Animals and Experiment Design

Fifty Wide-type C57BL/6J Male mice, weighting 18–20g (eight weeks), were purchased from Guangdong Medical Laboratory Animal Center (Guangdong, China) and were allowed free access to food and water in a restricted specific pathogen-free room with a controlled temperature (25°C) under 12 h light/12 h dark cycle. All animal experiments were performed according to the Criteria of the Medical Laboratory Animal Administrative Committee of Guangdong and the Guide for Care and Use of Laboratory Animals of Guangzhou Medical University. And the protocols were approved by the Ethic Committee for Experiment Research, General Hospital of Ningxia Medical University (2015–041). At the same time, we declared that the content of this study complies with the ARRIVE guidelines. The mice were randomly divided into five groups: control group, CS group, CS plus digoxin groups (0.02 mg/kg and 0.1 mg/kg) and digoxin (0.02 mg/kg) group, 10 mice per group. To establish the COPD mouse model, mice were exposed to CS that were produced by 9 filtered cigarettes (Plum brand, Guangdong Tobacco Industry Co., Ltd., Guangdong, China) for 4 h per day, 6 days per week, 24 weeks together in a whole-body exposure chamber. After 16-week CS exposure, mice in the CS plus digoxin groups were intragastrically treated with different doses of digoxin (Sigma, D6003) once a day, 6 days a week, 8 weeks together before exposure to CS. Meanwhile, mice in the CTL and CS groups were given an equal amount of CMC-Na (0.5%), which as a suspending agent for digoxin. After 8-week digoxin or CMC-Na administration, all mice were sacrificed and used to study the effects of digoxin on COPD.

Cell Culture and Treatment

The human lung adenocarcinoma cell lines (A549) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and cultured in DMEM containing 10% fetal bovine serum, 100 mg/L penicillin, and 100 mg/L streptomycin in a humidified incubator at 37°C with 5% (v/v) CO₂. When the cell abundance reached 60%–70%, A549 cells were treated with digoxin or S7959 (a Smad3 inhibitor) for 2 h before 48-h CSE (2%) treatment. Each

cell experiment was repeated five times. Digoxin and S7959 were dissolved in DMSO at a concentration of 50nM and 100μM, respectively. CSE was freshly prepared from Plum brand filtered cigarettes within 30 min prior to CSE treatment according to a described protocol.²² And prepared fresh CSE was regarded as 100%. All other culture reagents used in our study were purchased from Gibco (Carlsbad, CA, United States).

Assessment of Lung Function

Lung function was evaluated just as previously described.¹⁹ The total lung capacity (TLC), functional residual capacity (FRC), forced vital capacity (FVC), resistance index (RI) and forced expiration volume at 50ms (FEV₅₀) were obtained according to manufacturer's protocol.

Western Blot Analysis

Western blot analysis was performed as described by Li et al.¹⁹ After PVDF membranes were incubated with horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit secondary antibodies, western blotting images were obtained by Tanon 5200 chemiluminescence imaging system (Shanghai Tanon Science & Technology, Shanghai, China). Semi-quantitative analyses of immunoblots were performed using the Image J. The primary antibodies used in our study were as follows: mouse-anti-β-actin antibody (sc-47778, Santa Cruz Biotechnology, Dallas, TX), rabbit-anti-HIF-1α antibody (NB100479, Novus Biologicals, Littleton, Colorado, USA), mouse anti E-cadherin antibody (Cell Signaling Technology, Danvers, CA, United States), rabbit anti-Vimentin antibody (Cell Signaling Technology, Danvers, CA, United States), rabbit anti-ZO-1 antibody (RA231621, Cell Signaling Technology, Danvers, CA, United States), rabbit anti-phospho-Smad3 antibody (9523S, Cell Signaling Technology, Danvers, CA, United States), and rabbit-anti-Smad3 (9520T, Cell Signaling Technology, Danvers, CA, United States). β-actin was used as the internal control.

Real-Time PCR Analysis

Total RNA was extracted from lung tissues or A549 cells using Trizol reagent (Invitrogen) and reversely transcribed into cDNA using the Prime Script RT reagent Kit with gDNA Eraser (TAKARA, Japan). Primer sequences for target genes (HIF-1α, TGF-β1, Smad3, IL-6, IL-1β and TNF-α) were as follows: Mouse HIF-1α (Fwd 5'-GATGACGGCGACATGGTTTAC-3' and Rev 5'-CTCACTGGGCCATTTCTGTGT-3'); Mouse TGF-β1 (Fwd 5'-ATCTCGATTTTACCCTGGTGGT-3' and Rev 5'-CTCCCAAGGAAAGGTAGGTGATAGT-3'); Mouse Smad3 (Fwd 5'-AGATGACAGTGCAGCAGTGGGT-3' and Rev 5'-CAGCAGAGGAGAAGGGGTAAAGAG-3'); Mouse IL-1β (Fwd 5'-GCCTCGTGCTGTCTCGGACCCATAT-3' and Rev 5'-TCCTTTGAGGCCCAAGGCCACA-3'); Mouse IL-6 (Fwd 5'-TCACAGAAGGAGGGCTAAGGACC-3' and Rev 5'-TCACAGAAGGAGTGGCTAAGGACC-3'); Mouse TNF-α (Fwd 5'-CCCTCCTGGCCAACGGCATG-3' and Rev 5'-TCGGGGCAGCCTTGTCCTT-3'); mouse 18S (Fwd 5'-GCAATTATCCCCATGAACG-3' and Rev 5'-GGCCTCACTAAACCATCCAA-3'); Human HIF-1α (Fwd 5'-TGCTTGGTGTGCTGATTTGTGAACC-3' and Rev 5'-CTGTCCTGTGGTGACTTGTC-3'); Human TGF-β1 (Fwd 5'-AAGGACCTCGGCTGGAAGTG-3' and Rev 5'-CCGGGTTATGCTGGTTGTA-3'); Human Smad3 (Fwd 5'-GAGTGAAGATGGAGAAACAGTGAC-3' and Rev 5'-GTAGTAGGAGATGGAGCACCAGAAG-3'); Human GAPDH (Fwd 5'-TGACTTCAACAGCGACACCA-3' and Rev 5'-CACCTGTGCTGTAGCCAAA-3'). 18S and GAPDH were used as an internal control in mouse lung tissue and A549 cells, respectively. And all the primers were synthesized by Sangon Biotech (Shanghai, China).

Bronchial Alveolar Lavage Fluid (BALF) Analysis

Mice were sacrificed with 1% pentobarbital sodium (50 mg/kg, i.p). Then the lungs underwent lavage with 0.6 mL saline for three times. BALF was collected and centrifuged (800 g, 5 min, 4°C). Then the sediment cells were resuspended with 1mL saline for cell classification and counting. The cells were subjected to Giemsa staining for differential counting of neutrophils, macrophages and lymphocytes. The supernatant was stored at -80°C for pro-inflammatory cytokine detection by ELISA.

Lung Pathological Analysis

Left lungs were perfused with 10% buffered formalin and then immediately immersed and fixed in this fixative solution for 24 h. The lung tissues were embedded in paraffin, cut into 3-mm-thick-sections and then stained with hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS, Shanghai Sun Biotechnology, Shanghai, China) for histological examination. Goblet cells were identified by PAS staining. PAS-positive cells were quantified by a previously described semi-quantitative method with slight modification.^{23,24} Briefly, PAS-positive and total epithelial areas were measured by Image Pro-Plus, and the goblet cell metaplasia score was calculated as the percentage of the PAS-stained area to the total epithelial area after scoring 3 or 4 different areas per slide from 5 slides in each treatment group. Moreover, the average alveolar intercept of the lungs was measured by Image Pro-Plus.

Enzyme-Linked Immunosorbent Assay (ELISA)

BALF and cell supernatant were prepared for ELISA. The concentration of tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), TGF- β 1 and monocyte chemo-tactic protein-1 (MCP-1) was measured using the ELISA kit following the manufacturer's protocol (eBioscience Affymetrix, Santa Clara, CA, United States). The levels of Muc5ac and Muc5b in BALF were also measured, according to Lu et al.²⁵

Measurement of Body Weight and Liver, Spleen, Kidney Indices

All mice were weighed once a week during the first 16 weeks of CS exposure and twice a week during digoxin treatment. In addition, the liver, spleen, and kidney were blotted dry and weighed at the time of sampling. The ratios of liver, spleen and kidney weight to the body weight were counted as liver, spleen and kidney indices, respectively.

Hematocrit (HCT) Measurement

Briefly, at the terminal of chronic CS exposure, whole blood was collected into capillary tubes (0.5 mm outside diameter, VWR Scientific, Radnor, PA) via right ventricle puncture with K2EDTA as an anticoagulant and centrifuged at 7000 rpm for 5 min and read on a hematocrit chart (VWR Scientific).

Data Statistics

Data were analyzed with ANOVA or two-tailed Student's *t*-test. A one-way ANOVA followed by Bonferroni post-hoc test was used for comparisons between more than two groups. Data were presented as mean \pm SD, "n" means the number of animals or repeats in cell experiments. $P < 0.05$ and $P < 0.01$ were regarded as significant.

Results

Digoxin Protects Against CS-Induced Lung Function Decline and Hypoxia in Mice

To investigate the potential role of digoxin as a HIF-1 α inhibitor in CS-induced COPD, COPD mice induced by six-month consecutive CS exposure were treated with two doses of digoxin (0.02 mg/kg and 0.1 mg/kg). CS-exposed mice exhibited obvious lung function decline (Figure 1A–E), manifested by a decrease in FEV₅₀/FVC and higher values in TLC, FRC, FVC and RI compared with CTL group. Hematocrit, an indicator of chronic hypoxia, was increased in mice exposed to CS compared with CTL group (Figure 1F). The above lung injury indicators, including lung function decline and chronic hypoxia, were ameliorated by digoxin (mainly 0.1 mg/kg, TLC: CS group: $1.70 \pm 0.14\%$, CS+0.02 mg/kg group: $1.62 \pm 0.25\%$, CS+0.1 mg/kg group: $1.47 \pm 0.29\%$; FRC: CS group: $0.54 \pm 0.06\%$, CS+0.02 mg/kg group: $0.51 \pm 0.05\%$, CS+0.1 mg/kg group: $0.48 \pm 0.04\%$; FVC: CS group: $1.46 \pm 0.10\%$, CS+0.02 mg/kg group: $1.34 \pm 0.22\%$, CS+0.1 mg/kg group: $1.27 \pm 0.13\%$; Resistance: CS group: $1.38 \pm 0.17\%$, CS+0.02 mg/kg group: $1.012 \pm 0.12\%$, CS+0.1 mg/kg group: $0.98 \pm 0.06\%$; FEV₅₀/FVC: CS group: $0.52 \pm 0.13\%$, CS+0.02 mg/kg group: $0.62 \pm 0.07\%$, CS+0.1 mg/kg group: $0.67 \pm 0.04\%$; Cydn: CS group: $0.02 \pm 0.002\%$, CS+0.02 mg/kg group: $0.03 \pm 0.005\%$, CS+0.1 mg/kg group: $0.03 \pm 0.002\%$, percentage of the CTL group). These results demonstrate that digoxin protects against lung function decline and hypoxic changes in the COPD mice model.




Figure 1 Digoxin protects against CS-induced lung function decline and hypoxia in mice. To investigate the role of HIF-1 α on CS-induced COPD, mice exposed to CS for 6 months were intragastrically treated with digoxin (0.02 and 0.1 mg/kg). (A) TLC, (B) FRC, (C) FVC, (D) Resistance, (E) FEV₅₀/FVC and (F) Hematocrit were evaluated. ** $p < 0.01$ versus the control group; # $p < 0.05$ and ## $p < 0.01$ versus the CS group ($n = 9-10$ per group in mice).

Abbreviation: CS, cigarette smoke.

Digoxin Decreases CS-Induced or CSE-Induced Inflammation in Both Mice and A549 Cells

Long-term smoking can cause chronic inflammation in lungs, which is a contributing factor in COPD pathogenesis.²⁶ Digoxin attenuated CS-induced increases in the number of total inflammatory cells and macrophages in BALF (Figure 2A and B). Moreover, the mRNA levels of TNF- α , IL-6 and IL-1 β in lung tissues (Figure 2C–E) as well as the TNF- α , IL-6 and MCP-1 protein levels in BALF (Figure 2F–H) of CS-exposed mice were reduced by digoxin treatment (Total cell: CS group: 170.7 ± 55.310^4 /mL, CS+0.02 mg/kg group: 52.8 ± 17.410^4 /mL, CS+0.1 mg/kg group: 52.1 ± 25.610^4 /mL; Macrophages: CS group: 148.6 ± 44.910^4 /mL, CS+0.02 mg/kg group: 47.7 ± 14.610^4 /mL, CS+0.1 mg/kg group: 48.5 ± 25.510^4 /mL; IL-6: CS group: 19.81 ± 3.71 pg/mL, CS+0.02 mg/kg group: 16.83 ± 2.24 pg/mL, CS+0.1 mg/kg group: 12.82 ± 2.23 pg/mL; TNF- α : CS group: 17.81 ± 3.35 pg/mL, CS+0.02 mg/kg group: 14.31 ± 8.33 pg/mL, CS+0.1 mg/kg group: 12.7 ± 4.23 pg/mL; MCP-1: CS group: 437.1 ± 129.8 pg/mL, CS+0.02 mg/kg group: 238 ± 48.74 pg/mL, CS+0.1 mg/kg group: 239.6 ± 48.7 pg/mL). To extend these findings to the human system, A549 cells were exposed to 2% CSE for 48 h in the presence or absence of digoxin (50nM), and then pro-inflammatory cytokine levels in culture supernatant were measured. Consistently, digoxin treatment significantly reduced CSE-induced IL-6 and IL-8 release in A549 cells (IL-6: CSE group: 188.4 ± 25.52 pg/mL, CSE +Digoxin group: 155.9 ± 12.02 pg/mL; IL-8: CSE group: 165.7 ± 15.69 pg/mL, CSE +Digoxin group: 124.9 ± 28.46 pg/mL, Figure 2I and J). Taken together, these results suggest that digoxin reduces CS-induced or CSE-induced inflammatory responses in both mouse lungs and A549 cells.

Digoxin Attenuates CS-Induced Emphysema, Airway Goblet Cell Hypertrophy and Hyperplasia, and Airway Mucus Hyper-Secretion in Mice

Airspace enlargement resulting from alveolar destruction was found in lungs of CS-exposed mice. As shown in Figure 3A, the mean linear intercept in the lungs was significantly increased by CS exposure, which was alleviated by digoxin administration (Average alveolar intercept: CS group: 56.73 ± 5.94 μ m; CS+0.02 mg/kg group: 42.56 ± 3.58 μ m, CS+0.1 mg/kg group: 48.69 ± 3.37 μ m, percentage of the CTL group). Goblet cell hypertrophy and hyperplasia can induce mucus hyper-secretion in the airway, which is one of the important factors in predicting the




Figure 2 Digoxin decreases CS-induced or CSE-induced inflammation in both mice and A549 cells. **(A and B)** The number of total inflammatory cells and macrophages in BALF were measured by cell counting. The mRNA levels of TNF- α , IL-6, and IL-1 β in mouse lung tissues were measured by real-time PCR **(C–E)**. The protein levels of TNF- α , IL-6 and MCP-1 in BALF **(F–H)** were measured by ELISA. To further explore the effect of HIF-1 α on CSE-induced inflammatory responses in vitro, A549 cells were treated with digoxin for 1 h before 48-h CSE exposure. IL-6 and IL-8 levels in cell supernatant **(I and J)** were measured by ELISA. * $p < 0.05$ and ** $p < 0.01$ versus the control group; # $p < 0.05$ and ## $p < 0.01$ versus the CS group ($n = 8$ –10 per group in mice, $n = 5$ per group in A549 cells).

Abbreviation: CS, cigarette smoke; CSE, cigarette smoke extract.

incidence and mortality of COPD.²⁷ The PAS staining showed that compared with the CTL group, the number of goblet cells in the airway epithelium and the levels of mucin (Muc5ac and Muc5b) in BALF of CS group were significantly increased. Digoxin (0.02 and 0.1 mg/kg) could effectively inhibit CS exposure-induced proliferation of airway goblet cells (PAS positive staining area of Epithelium: CS group: $0.128 \pm 0.008\%$, CS+0.02 mg/kg group: $0.06 \pm 0.03\%$, CS+0.1 mg/kg group: $0.04 \pm 0.01\%$, percentage of the CTL group, **Figure 3B**). But only high dose of digoxin (0.1 mg/kg) can effectively inhibit the higher levels of Muc5ac and Muc5b in BALF induced by CS exposure (Muc5ac: CS group: 2.1 ± 0.23 , CS+0.02 mg/kg group: 1.82 ± 0.39 , CS+0.1 mg/kg group: 1.61 ± 0.30 ;




Figure 3 Digoxin attenuates CS-induced emphysema, airway goblet cell hypertrophy and hyperplasia, and airway mucus hyper-secretion in mice. Lung tissue sections were subjected to H&E and PAS staining. **(A)** The mean linear intercept ($\times 100$ magnification) and **(B)** goblet cell hyperplasia score ($\times 400$ magnification) in mouse lungs were analyzed using Image-Pro Plus 6.0 software (\rightarrow point to goblet cell). The protein levels of Muc5ac and Muc5b in BALF were measured by ELISA **(C and D)**. ** $p < 0.01$ versus the control group; # $p < 0.05$ and ### $p < 0.01$ versus the CS group ($n = 5$ per group in Fig. **(A and B)**, $n = 8-10$ per group in Fig. **(C and D)**).

Abbreviation: CS, cigarette smoke.

Muc5b: CS group: 1.91 ± 0.29 , CS+0.02 mg/kg group: 1.66 ± 0.25 , CS+0.1 mg/kg group: 1.38 ± 0.40 , percentage of the CTL group, Figure 3C and D). These results indicate that digoxin attenuates emphysema, goblet cell hypertrophy and hyperplasia, and mucus hyper-secretion in the airway of COPD mice.

Digoxin Has No Significant Effect on the Liver, Spleen and Kidney Indices and Body Weight of CS-Exposed Mice

CS exposure increased the kidney index (Figure 4C) but decreased the body weight (Figure 4D) of mice, and it had no effect on liver and spleen indices (Figure 4A and B). Furthermore, digoxin (0.02 and 0.1 mg/kg) had no significant effect on the liver, spleen and kidney indices (Liver index: CS group: $0.048 \pm 0.003\%$, CS+0.02 mg/kg group: $0.04 \pm 0.004\%$, CS+0.1 mg/kg group: $0.05 \pm 0.01\%$ Spleen index: CS group: $0.003 \pm 0.000\%$, CS+0.02 mg/kg group: $0.003 \pm 0.000\%$, CS+0.1 mg/kg group: $0.003 \pm 0.000\%$; Kidney index: CS group: $0.012 \pm 0.000\%$, CS+0.02 mg/kg group: $0.013 \pm 0.001\%$, CS+0.1 mg/kg group: $0.013 \pm 0.002\%$, percentage of the CTL group, Figure 4A–C) and body weight of CS-exposed mice (Weight: CS group: $27.08 \pm 2.77\%$, CS+0.02 mg/kg group: $27.6 \pm 2.36\%$, CS+0.1 mg/kg group: $27 \pm 1.65\%$, Figure 4D). These results show that the doses of digoxin (0.02 and 0.1 mg/kg) used in this study have no apparent toxicity on important organs of mice.

Digoxin Attenuates CS-Induced or CSE-Induced EMT in Both Mice and A549 Cells

CS or CSE exposure can induce EMT in vivo or vitro.^{22,23} Consistent with this, our results showed that CS exposure decreased the level of epithelial marker (E-cadherin, CS group: $0.54 \pm 0.06\%$, percentage of the CTL group) and




Figure 4 Digoxin has no significant effect on the liver, spleen and kidney indices and body weight of CS-exposed mice. (A) liver index, (B) spleen index, (C) kidney index and (D) body weight of mice were measured. All data are shown as the mean \pm SD; Statistical significance was assessed by one-way ANOVA. * $p < 0.05$ and ** $p < 0.01$ versus control group ($n = 8-10$ per group in mice).

Abbreviation: CS, cigarette smoke.

increased the level of mesenchymal markers (Fibronectin, CS group: $0.43 \pm 0.14\%$ and Vimentin, CS group: $0.88 \pm 0.12\%$) in mouse lungs (Figure 5A). Treatment with high concentration of digoxin (0.1 mg/kg) significantly inhibited CS-induced EMT and HIF-1 α expression increases (Fibronectin: CS+0.02 mg/kg group: $0.37 \pm 0.16\%$, CS+0.1 mg/kg group:




Figure 5 Digoxin attenuates CS-induced or CSE-induced EMT in both mice and A549 cells. **(A)** The expressions of Fibronectin, E-cadherin, HIF-1 α , and vimentin in lung tissues were measured by Western blot. To further explore the effect of HIF-1 α on CSE-induced EMT in vitro, A549 cells were treated with digoxin before 48-h CSE exposure. **(B)** The expressions of ZO-1, HIF-1 α , and vimentin in A549 cells were measured by Western blot. * $p < 0.05$ and ** $p < 0.01$ versus the control group; # $p < 0.05$ versus the CS group ($n = 5$ per group in mice, $n = 5$ per group in A549 cells).

Abbreviation: CS, cigarette smoke; CSE, cigarette smoke extract.

0.22 ± 0.06%; E-cadherin, CS+0.02 mg/kg group: 0.68 ± 0.09%, CS+0.1 mg/kg group: 0.74 ± 0.14%; HIF-1 α : CS +0.02 mg/kg group: 0.86 ± 0.18%, CS+0.1 mg/kg group: 0.71 ± 0.11%; Vimentin: CS+0.02 mg/kg group: 0.77 ± 0.10%, CS+0.1 mg/kg group: 0.71 ± 0.09%). Moreover, our in vitro data indicated that 2% CSE stimulation for 48 h significantly decreased the protein expression of ZO-1 (CS group: 0.31 ± 0.09%, percentage of the CTL group) but increased the level of Vimentin (CS group: 1.53 ± 0.14%, percentage of the CTL group) and HIF-1 α (CS group: 0.60 ± 0.17%, percentage of the CTL group, Figure 5B). These changes were significantly inhibited by digoxin treatment in A549 cells (ZO-1: CS + Digoxin group: 0.58 ± 0.31%, Vimentin: CS + Digoxin group: 1.31 ± 0.13%, HIF-1 α : CS + Digoxin group: 0.43 ± 0.16%, percentage of the CTL group, Figure 5B). These results show that HIF-1 α contributes to CS-induced EMT both in vivo and in vitro.

Digoxin Attenuates CS-Induced or CSE-Induced EMT Possibly Through HIF-1 α /TGF- β 1/Smad3 Signaling Pathway

TGF- β 1/Smad signaling pathway plays a crucial role in triggering EMT,¹⁷ and HIF-1 α protein synthesis is reported to regulate the TGF- β 1/Smad signaling pathway.¹⁷ Therefore, we examined the effects of digoxin on HIF-1 α , TGF- β 1, and Smad mRNA levels both in vivo and in vitro. As Figure 6A–F showed, CS or CSE exposure resulted in significant increase of HIF-1 α , TGF- β 1, and Smad mRNA levels both in mice and A549 cells, which was attenuated by digoxin treatment. To further explore the effect of TGF- β 1/Smad pathway on CSE-induced EMT, we pretreated CSE-stimulated A549 cells with S7959 that can block the activation of Smad2/3. Pretreatment with S7959 inhibited the CSE-induced phosphorylation of Smad3 (CS group: 1.00 ± 0.15%, CS+S7959 group: 0.80 ± 0.1%, percentage of the CTL group, Figure 6G) and alleviated CSE-induced decrease of E-cadherin protein expression (CS group: 0.62 ± 0.14%, CS+S7959 group: 1.03 ± 0.26%, percentage of the CTL group, Figure 6H). These results indicate that digoxin suppresses CSE-induced EMT possibly through the HIF1- α /TGF- β 1/Smad pathway.

Discussion

In the present study, we investigated the possible role of the HIF-1 α inhibitor in the development of COPD and determined whether digoxin exerted its anti-EMT effects via the blockade of HIF-1 α /TGF- β 1/Smad signaling pathway. Our study showed that digoxin, as a HIF-1 α inhibitor, decreased CS-induced inflammation and EMT both in vivo and in vitro. Moreover, digoxin alleviated CS-induced lung function decline, emphysema, and airway goblet cell hyperplasia in COPD mouse model. More importantly, our findings for the first time revealed that HIF-1 α inhibitor contributed to the development of EMT in CS-induced COPD possibly through TGF- β 1/Smad3 signaling pathway.

CS, a major risk factor of COPD, can cause pulmonary inflammation, airway obstruction, and alveolar structure changes.²⁸ In this study, COPD mouse model was induced by CS exposure for six months to simulate the development of COPD in human. Moreover, EMT is implicated in respiratory structural remodeling and airway fibrosis in COPD and related to airflow obstruction,¹⁴ but no definitive treatment has been shown to effectively inhibit EMT in COPD. Therefore, it is urgent for us to find a new and effective method to prevent the development and improve the prognosis of COPD. Our study showed HIF-1 α contributed to inflammatory responses, emphysema, goblet cell hypertrophy and proliferation in airway epithelium, airway mucus hypersecretion, and EMT in CS-induced COPD. It seems that HIF-1 α is a promising intervention target of preventing the development and improving the prognosis of COPD.

The knockout of HIF-1 α attenuates inflammatory responses of proximal colon cancer²⁹ and alleviates LPS-induced sepsis.³⁰ Moreover, HIF-1 α promotes hypoxia-induced inflammatory responses by activating the pathway of EGFR/PI3K/AKT.¹⁷ Consistent with these findings, our study showed that digoxin could alleviate CS-induced inflammatory cell infiltration and pro-inflammatory factor release in mouse lungs. At the same time, digoxin can significantly reduce CSE-induced secretion of IL-6 and IL-8 in A549 cells. However, the mechanism by which HIF-1 α promotes CS-induced inflammation was not studied in depth. HIF-1 α may inhibit the innate and adaptive immunity of airway epithelium,³¹ which will be focused in our future research.

Airway mucus hypersecretion, one of the important factors predicting the incidence and mortality of COPD,²⁷ is closely related to airway hyper-reactivity³² and airway obstruction. Studies have shown that controlling airway mucus




Figure 6 Digoxin attenuates CS-induced or CSE-induced EMT possibly through the HIF-1α/TGF-β1/Smad3 signaling pathway. The mRNA levels of HIF-1α, TGF-β1 and Smad3 in lung tissues or A549 cells were measured by real-time PCR (**A–F**). To further determine the role of Smad3 in COPD-associated EMT, CSE-exposed A549 cells were pretreated with S7959 (a Smad3 inhibitor) for 1h before 48h CSE stimulation. The protein levels of p-Smad3 and E-cadherin in A549 cells were measured by Western Blot (**G** and **H**). * $p < 0.05$ and ** $p < 0.01$ versus the control group; # $p < 0.05$ and ### $p < 0.01$ versus the CS group ($n = 5$ per group in mice, $n = 5$ per group in A549 cells). **Abbreviation:** CS, cigarette smoke; CSE, cigarette smoke extract.

hyper-secretion can effectively prevent acute exacerbation of COPD and improve the quality of life of COPD patients.³³ However, there is a lack of effective treatment for airway mucus hyper-secretion. Previous study has demonstrated that HIF-1α promotes hyperplasia of airway goblet cells via epidermal growth factor receptor-mediated signaling pathways.³⁴

In addition, the binding of HIF-1 α to conserved region of *MUC5AC* gene promoter has been confirmed, and it means that HIF-1 α signaling pathway may be involved in up-regulation of airway mucus production.³⁵ Our results also indicate that the administration of digoxin inhibited airway goblet cell proliferation and mucus hyper-secretion, indicating that HIF-1 α is a potential target for treating mucus hyper-secretion in COPD.

Pathological changes in COPD are characterized by emphysema, small airway remodeling and peribronchiolar fibrosis.² EMT in airway epithelium is increased both in COPD patients and smokers with normal lung function.²³ Our results also showed that CS exposure induced EMT both in vivo and in vitro. Moreover, EMT is involved in the respiratory structural remodeling and airway fibrosis in COPD,¹⁴ and contributes greatly to the occurrence and progression of COPD.^{13,18,34,36} Therefore, there is an enormous need to find new treatment targets for EMT in COPD. HIF-1 α plays a key role in EMT of renal fibrosis and mammary cancer cells.^{15,16} But so far, the role of HIF-1 α on EMT in CS-induced COPD has not been reported. Our results suggested that administration of digoxin could significantly inhibit CS-induced increase of HIF-1 α protein expression and alleviate CS-induced EMT in mouse lung tissues and A549 cells. Some studies have shown that CS exposure induces the formation of EMT mainly through Smad signaling pathways.²² Besides, HIF-1 α can activate TGF- β 1/Smad signaling pathway.³⁷ This study also indicated that digoxin inhibited CS-induced increases of HIF-1 α , TGF β 1, Smad3 mRNAs in mouse lung tissues and A549 cells. Moreover, the administration of Smad3 inhibitor was found to significantly inhibit the activation of Smad3 and CSE-induced EMT in A549 cells. Therefore, we believe that digoxin inhibits COPD-associated EMT through HIF-1 α /TGF- β 1/Smad3 signaling pathway. This demonstrates that HIF-1 α may be a new therapeutic target for EMT in CS-induced COPD.

Conclusion

In summary, our study showed that digoxin as a HIF-1 α inhibitor could significantly inhibit CS-induced emphysema, inflammatory responses, airway mucus hypersecretion, lung function decline and EMT. More importantly, we first found that digoxin could inhibit CS-induced EMT in COPD through HIF-1 α /TGF- β 1/Smad3 signaling pathway. This study provides evidence for HIF-1 α to contribute to the progression of COPD by promoting CS-induced EMT, inflammation, airway mucus hypersecretion and emphysema. However, there are still shortcomings in this study. First of all, it is still necessary to use enzyme activity experiments, molecular docking assays, and surface plasmon resonance technology to prove the direct binding effect of digoxin and HIF-1 α . Secondly, further knockdown of HIF-1 α in cells or animals is needed to observe its effects on inflammation, mucus secretion, and EMT-related proteins, thereby confirming the validity of our results.

Abbreviations

BALF, bronchial alveolar lavage fluid; COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; CSE, cigarette smoke extract; EMT, epithelial–mesenchymal transition; MCP-1, monocyte chemoattractant protein-1; HIF-1 α , hypoxia-inducible factor-1 α .

Data Sharing Statement

The provided data supporting the findings of this study are included within the article.

Ethics Approval

Ethical clearance was sought from the Ethics Committee of the General Hospital of Ningxia Medical University (2015-041) and follows the ARRIVE guidelines on the protection of laboratory animals used for scientific causes.

Acknowledgments

The authors acknowledge the laboratory provided by the Guangzhou Institute of Respiratory Health. This paper has been uploaded to Research Square as a preprint: <https://doi.org/10.21203/rs.3.rs-3789467/v1>.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This work is supported by the National Natural Science Foundation of China (Grant No. 81560011) and Special Scientific Research Program Project of Shaanxi Provincial Department of Education (Grant No.22JK0341).

Disclosure

The authors have no conflicts of interest to declare in this work.

References

1. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10(5):447–458. doi:10.1016/S2213-2600(21)00511-7
2. Lopez-Campos JL, Soler-Cataluna JJ, Miravittles M. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2019 report: future challenges. *Arch Bronconeumol*. 2020;56(2):65–67. doi:10.1016/j.arbres.2019.06.001
3. Agusti A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. *Eur Respir J*. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023
4. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. *Annu Rev Pathol*. 2009;4:435–459. doi:10.1146/annurev.pathol.4.110807.092145
5. Distler JH, Wenger RH, Gassmann M, et al. Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. *Arthritis Rheum*. 2004;50(1):10–23. doi:10.1002/art.11425
6. Shukla SD, Walters EH, Simpson JL, et al. Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease. *Respirology*. 2020;25(1):53–63. doi:10.1111/resp.13722
7. Guan R, Wang J, Li Z, et al. Sodium tanshinone IIA sulfonate decreases cigarette smoke-induced inflammation and oxidative stress via blocking the activation of MAPK/HIF-1 α signaling pathway. *Front Pharmacol*. 2018;9:263. doi:10.3389/fphar.2018.00263
8. X ZH, J YJ, A ZS, et al. HIF-1 α promotes inflammatory response of chronic obstructive pulmonary disease by activating EGFR/PI3K/AKT pathway. *Eur Rev Med Pharmacol Sci*. 2018;22(18):6077–6084. doi:10.26355/eurrev_201809_15946
9. Polosukhin VV, Cates JM, Lawson WE, et al. Hypoxia-inducible factor-1 signalling promotes goblet cell hyperplasia in airway epithelium. *J Pathol*. 2011;224(2):203–211. doi:10.1002/path.2863
10. Besiktepe N, Kayalar O, Ersen E, et al. The copper dependent-lysyl oxidases contribute to the pathogenesis of pulmonary emphysema in chronic obstructive pulmonary disease patients. *J Trace Elem Med Biol*. 2017;44:247–255. doi:10.1016/j.jtemb.2017.08.011
11. He H, Ji X, Cao L, et al. Medicine targeting epithelial-mesenchymal transition to treat airway remodeling and pulmonary fibrosis progression. *Can Respir J*. 2023;2023:3291957. doi:10.1155/2023/3291957
12. A B-GE, Vargas-Guerrero B, E G-L-L, et al. Molecular changes underlying pulmonary emphysema and chronic bronchitis in chronic obstructive pulmonary disease: an updated review. *Histol Histopathol*. 2024;39(7):805–816. doi:10.14670/HH-18-699
13. S EM, Sharma P, V GA, et al. Epithelial-mesenchymal transition is driven by transcriptional and post transcriptional modulations in COPD: implications for disease progression and new therapeutics. *Int J Chron Obstruct Pulmon Dis*. 2019;14:1603–1610. doi:10.2147/COPD.S208428
14. Nowrin K, S SS, Peterson G, et al. Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways: fibrosis, remodeling and cancer. *Expert Rev Respir Med*. 2014;8(5):547–559. doi:10.1586/17476348.2014.948853
15. Li W, Xue D, Xue M, et al. Fucoidan inhibits epithelial-to-mesenchymal transition via regulation of the HIF-1 α pathway in mammary cancer cells under hypoxia. *Oncol Lett*. 2019;18(1):330–338. doi:10.3892/ol.2019.10283
16. Sun S, Ning X, Zhang Y, et al. Hypoxia-inducible factor-1 α induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. *Kidney Int*. 2009;75(12):1278–1287. doi:10.1038/ki.2009.62
17. Dimitrova Y, J GA, Mittal N, et al. TFAP2A is a component of the ZEB1/2 network that regulates TGF β 1-induced epithelial to mesenchymal transition. *Biol Direct*. 2017;12(1):8. doi:10.1186/s13062-017-0180-7
18. Q MM, Reid D, Ward C, et al. Transforming growth factor (TGF) β 1 and Smad signalling pathways: a likely key to EMT-associated COPD pathogenesis. *Respirology*. 2017;22(1):133–140. doi:10.1111/resp.12882
19. Li D, Wang J, Sun D, et al. Tanshinone IIA sulfonate protects against cigarette smoke-induced COPD and down-regulation of CFTR in mice. *Sci Rep*. 2018;8(1):376. doi:10.1038/s41598-017-18745-5
20. Zhang H, Z QD, S TY, et al. Digoxin and other cardiac glycosides inhibit HIF-1 α synthesis and block tumor growth. *Proc Natl Acad Sci U S A*. 2008;105(50):19579–19586. doi:10.1073/pnas.0809763105
21. Yoshida T, Zhang H, Iwase T, et al. Digoxin inhibits retinal ischemia-induced HIF-1 α expression and ocular neovascularization. *FASEB J*. 2010;24(6):1759–1767. doi:10.1096/fj.09-145664
22. Guan S, Xu W, Han F, et al. Ginsenoside Rg1 attenuates cigarette smoke-induced pulmonary epithelial-mesenchymal transition via inhibition of the TGF- β 1/Smad pathway. *Biomed Res Int*. 2017;2017:7171404. doi:10.1155/2017/7171404
23. Milara J, Peiro T, Serrano A, et al. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. *Thorax*. 2013;68(5):410–420. doi:10.1136/thoraxjnl-2012-201761

24. Zhang K, Wang J, Jiang H, et al. Tanshinone IIA inhibits lipopolysaccharide-induced MUC1 overexpression in alveolar epithelial cells. *Am J Physiol Cell Physiol.* **2014**;306(1):C59–C65. doi:10.1152/ajpcell.00070.2013
25. Lu W, Li D, Hu J, et al. Hydrogen gas inhalation protects against cigarette smoke-induced COPD development in mice. *J Thorac Dis.* **2018**;10(6):3232–3243. doi:10.21037/jtd.2018.05.93
26. Wang W, Zha G, J ZJ, et al. Berberine attenuates cigarette smoke extract-induced airway inflammation in mice: involvement of TGF-beta1/Smads signaling pathway. *Curr Med Sci.* **2019**;39(5):748–753. doi:10.1007/s11596-019-2101-8
27. Curran DR, Cohn L. Advances in mucous cell metaplasia: a plug for mucus as a therapeutic focus in chronic airway disease. *Am J Respir Cell Mol Biol.* **2010**;42(3):268–275. doi:10.1165/rcmb.2009-0151TR
28. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet.* **2018**;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
29. N MD, E DJ, N TP, et al. HIF1alpha deficiency reduces inflammation in a mouse model of proximal colon cancer. *Dis Model Mech.* **2015**;8(9):1093–1103. doi:10.1242/dmm.019000
30. Peyssonnaud C, Cejudo-Martin P, Doedens A, et al. Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. *J Immunol.* **2007**;178(12):7516–7519. doi:10.4049/jimmunol.178.12.7516
31. Polke M, Seiler F, M LP, et al. Hypoxia and the hypoxia-regulated transcription factor HIF-1alpha suppress the host defence of airway epithelial cells. *Innate Immun.* **2017**;23(4):373–380. doi:10.1177/1753425917698032
32. M EC, S RD, Ttofali F, et al. The polymeric mucin Muc5ac is required for allergic airway hyperreactivity. *Nat Commun.* **2015**;6:6281. doi:10.1038/ncomms7281
33. Lai H, Rogers DF. New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways. *J Aerosol Med Pulm Drug Deliv.* **2010**;23(4):219–231. doi:10.1089/jamp.2009.0802
34. E MJ, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. *N Engl J Med.* **2011**;365(17):1567–1575. doi:10.1056/NEJMoa1106955
35. W YH, Williams OW, Chandra D, et al. Central role of Muc5ac expression in mucous metaplasia and its regulation by conserved 5' elements. *Am J Respir Cell Mol Biol.* **2007**;37(3):273–290. doi:10.1165/rcmb.2005-0460OC
36. Xia H, Xue J, Xu H, et al. Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIR. *Toxicology.* **2019**;422:84–94. doi:10.1016/j.tox.2019.05.009
37. Mingyuan X, Qianqian P, Shengquan X, et al. Hypoxia-inducible factor-1alpha activates transforming growth factor-beta1/Smad signaling and increases collagen deposition in dermal fibroblasts. *Oncotarget.* **2018**;9(3):3188–3197. doi:10.18632/oncotarget.23225

International Journal of Chronic Obstructive Pulmonary Disease

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

Dovepress
Taylor & Francis Group